Patents by Inventor Heather Van Epps

Heather Van Epps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IL-13 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20260116963
    Abstract: The present application provides anti-IL-13 antibodies and antigen binding fragments thereof. Such antibodies and antigen binding fragments thereof may be used in methods for the treatment and/or prevention of an immunological disease or disorder.
    Type: Application
    Filed: January 3, 2025
    Publication date: April 30, 2026
    Inventors: Adam ROOT, Jaileene HERNANDEZ ESCALANTE, Nadine SHABAN, Monica MENZENSKI, Kristen JOHNSON, Brinda MONIAN, Todd ASHWORTH, Kapil MAYAWALA, Heather VAN EPPS, Tanvi Krishnakumar GAWDE, Vikram SADINENI
  • Anti-PD-L1 antibodies and antibody-drug conjugates
    Patent number: 12421312
    Abstract: Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 23, 2025
    Assignee: Seagen Inc.
    Inventors: Byron Hua Kwan, Heather Van Epps, Andrew Waight, Scott Jeffrey, Ryan Lyski
  • Combination Therapy
    Publication number: 20230270877
    Abstract: Provided herein are methods of treating cancer with an antibody that binds an immune cell engager in combination with an antibody-drug conjugate.
    Type: Application
    Filed: April 28, 2023
    Publication date: August 31, 2023
    Applicant: Seagen Inc.
    Inventors: Shyra Gardai, Alyson Smith, Kerry Klussman, Bernard Liu, Heather Van Epps
  • METHODS OF TREATING MULTIPLE MYELOMA
    Publication number: 20230118517
    Abstract: Provided herein are methods of treating multiple myeloma (MM) using specific doses of an anti-B-cell migration antigen (BCMA) antibody, various dosing regimens, and optionally combination therapy with dexamethasone, an immunomodulatory agent (e.g., pomalinamide), an anti-CD38 antibody or antigen binding fragment thereof (e.g., daratumumab), and a gamma secretase inhibitor (GSI), and/or various combinations thereof.
    Type: Application
    Filed: March 25, 2021
    Publication date: April 20, 2023
    Inventors: Mary Campbell, Heather Van Epps, Haley Neff-LaFord, Celine Fabienne Jacquemont, David Taft, Hong Li
  • ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20210101982
    Abstract: Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 8, 2021
    Inventors: Byron Hua Kwan, Heather Van Epps, Andrew Waight